litlas
Log inCreate account

Elise C. Kohn

Active 1988–2025

110
Papers
23,229
Citations
81
h-index
104
i10-index

Citations

Citations per year for Elise C. Kohn1964: 1 citations1987: 1 citations1988: 1 citations1989: 2 citations1990: 7 citations1991: 6 citations1992: 19 citations1993: 26 citations1994: 57 citations1995: 38 citations1996: 43 citations1997: 67 citations1998: 55 citations1999: 58 citations2000: 63 citations2001: 70 citations2002: 172 citations2003: 259 citations2004: 338 citations2005: 341 citations2006: 288 citations2007: 217 citations2008: 189 citations2009: 160 citations2010: 176 citations2011: 143 citations2012: 148 citations2013: 121 citations2014: 143 citations2015: 170 citations2016: 164 citations2017: 169 citations2018: 162 citations2019: 598 citations2020: 612 citations2021: 631 citations2022: 505 citations2023: 377 citations2024: 503 citations2025: 249 citations2026: 6 citations1965–1986: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,697 citing papers, 28.9% of this breakdownChina: 1,190 citing papers, 12.7% of this breakdownUnited Kingdom: 570 citing papers, 6.1% of this breakdownItaly: 520 citing papers, 5.6% of this breakdownGermany: 396 citing papers, 4.2% of this breakdownCanada: 328 citing papers, 3.5% of this breakdownFrance: 276 citing papers, 3% of this breakdownJapan: 263 citing papers, 2.8% of this breakdownAustralia: 243 citing papers, 2.6% of this breakdownSpain: 215 citing papers, 2.3% of this breakdownIndia: 214 citing papers, 2.3% of this breakdownNetherlands: 192 citing papers, 2.1% of this breakdown
0%28.9%Other 23.9%

Institutions

Fields

  • Medicine42.2%
  • Biochemistry, Genetics and Molecular Biology38.8%
  • Chemistry7.8%
  • Immunology and Microbiology3%
  • Computer Science2.8%
  • Neuroscience1.5%
  • Other3.9%

Topics

  • Ovarian cancer diagnosis and treatment4.8%
  • PARP inhibition in cancer therapy4.1%
  • Advanced Proteomics Techniques and Applications3%
  • Gene expression and cancer classification1.9%
  • DNA Repair Mechanisms1.9%
  • Angiogenesis and VEGF in Cancer1.6%
  • Other82.7%

Coauthors

All papers

Open in search
  1. Ovarian cancer

    Authors: Gordon C. Jayson, Elise C. Kohn, Henry C Kitchener, Jonathan A. Ledermann - The Lancet 2014 cited by 1,873

  2. The MAPK pathway across different malignancies: A new perspective

    Authors: Mauricio Burotto, Victoria L. Chiou, Jung‐Min Lee, Elise C. Kohn - Cancer 2014 cited by 985

  3. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

    Authors: Panagiotis A. Konstantinopoulos, Su-Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle, Elizabeth K. Lee, Elise C. Kohn, Linda Duska, Marta A. Crispens, Alexander Olawaiye, Ira Winer, Lisa Barroilhet, Siqing Fu, Michael McHale, Russell J. Schilder, Anniina Färkkilä, Dipanjan Chowdhury, Jennifer Curtis, Roxanne Quinn, Brittany Bowes, Alan D. D’Andrea, Geoffrey I. Shapiro, Ursula A. Matulonis - The Lancet Oncology 2020 cited by 232

  4. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

    Authors: William P. Tew, Christina Lacchetti, Annie Ellis, Kathleen Maxian, Susana Banerjee, Michael A. Bookman, Monica B. Jones, Jung‐Min Lee, Stéphanie Lheureux, Joyce F. Liu, Kathleen N. Moore, Carolyn Y. Muller, Patricia Rodríguez, Christine Walsh, Shannon N. Westin, Elise C. Kohn - Journal of Clinical Oncology 2020 cited by 310

  5. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    Authors: Ignace Vergote, Antonio González-Martı́n, Domenica Lorusso, Charlie Gourley, Mansoor Raza Mirza, Jean‐Emmanuel Kurtz, Aikou Okamoto, Kathleen N. Moore, Frédéric Kridelka, Iain A. McNeish, Alexander Reuß, Bénédicte Votan, Andreas du Bois, Sven� Mahner, I. L. Ray-Coquard, Elise C. Kohn, Jonathan S. Berek, David S.P. Tan, Nicoletta Colombo, Rongyu Zang, Nicole Concin, Dearbhaile M. O’Donnell, Alejandro Rauh-Hain, C. Simon Herrington, Christian Marth, Andrés Poveda, Keiichi Fujiwara, Gavin Stuart, Amit M. Oza, Michael A. Bookman, Sven� Mahner, Alexander Reuß, Andreas du Bois, Christoph Grimm, Christian Marth, Regina Berger, Nicole Concin, Ting‐Chang Chang, Kazunori Ochiai, Val Gebski, Alison Davis, Philip Beale, Ignace Vergote, Frédéric Kridelka, Hannelore Denys, Vincent Vandecaveye, Francisco José Cândido dos Reis, Maria Del Pilar Estevez-Diz, Gavin Stuart, Helen Mackay, Mark S. Carey, David Cibula, Pavel Dundr, Oliver Dorigo, Jonathan S. Berek, Dearbhaile M. O’Donnell, Feras Abu Saadeh, Ingrid Boere, Christianne Lok, Pluvio Coronado, Nelleke Ottevanger, David S.P. Tan, Joseph Ng, Antonio Gonzalez Martin, Ana Oaknin, Andrés Poveda, Alejandro Perez Fidalgo, Alejandro Rauh-Hain, Karen H. Lu, Carlos López-Zavala, Eva María Gómez-García, Isabelle Ray-Coquard, Xavier Paolettí, Jean‐Emmanuel Kurtz, Florence Joly, Bénédicte Votan, Michael A. Bookman, Kathleen Moore, Rebecca C. Arend, Keiichi Fujiwara, Hiroyuki Fujiwara, Kosei Hasegawa, Ilan Bruchim, Dalia Tsoref, Katsutoshi Oda, Aikou Okamoto, Takayuki Enomoto, Dayana Michel, Hee‐Seung Kim, Jung‐Yun Lee, Asima Mukhopadhyay, Dionyssios Katsaros, Nicoletta Colombo, Sandro Pignata, Domenica Lorusso, Giovanni Scambia, Elise C. Kohn, Jungmin Lee, Iain A. McNeish, Shibani Nicum and 16 more - The Lancet Oncology 2022 cited by 142

  6. Use of proteomic patterns in serum to identify ovarian cancer

    Authors: Emanuel F. Petricoin, Ali M. Ardekani, Ben A. Hitt, Peter J. Levine, Vincent A. Fusaro, Seth M. Steinberg, Gordon B. Mills, Charles B. Simone, David A. Fishman, Elise C. Kohn, Lance A. Liotta - The Lancet 2002 cited by 3,256

  7. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline

    Authors: Panagiotis A. Konstantinopoulos, Barbara M. Norquist, Christina Lacchetti, Deborah K. Armstrong, Rachel N. Grisham, Paul J. Goodfellow, Elise C. Kohn, Douglas A. Levine, Joyce F. Liu, Karen H. Lu, Dorinda Sparacio, Christina M. Annunziata - Journal of Clinical Oncology 2020 cited by 379

  8. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

    Authors: Jung‐Min Lee, Jayakumar R. Nair, Alexandra S. Zimmer, Stanley Lipkowitz, Christina M. Annunziata, Maria J. Merino, Elizabeth M. Swisher, Maria I. Harrell, Jane B. Trepel, Min-Jung Lee, Mohammadhadi Bagheri, Dana‐Adriana Botesteanu, Seth M. Steinberg, Lori M. Minasian, Irene Ekwede, Elise C. Kohn - The Lancet Oncology 2018 cited by 212

  9. Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update

    Authors: William P. Tew, Christina Lacchetti, Elise C. Kohn, for the PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel - Journal of Clinical Oncology 2022 cited by 114

  10. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

    Authors: Joyce F. Liu, Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, David Cella, William P. Tew, Noelle G. Cloven, Carolyn Y. Muller, David P. Bender, Richard G. Moore, David P. Michelin, Steven E. Waggoner, Melissa A. Geller, Keiichi Fujiwara, Stacy D. D'Andre, Michael Carney, Angeles Alvarez Secord, Katherine M. Moxley, Michael A. Bookman - Journal of Clinical Oncology 2022 cited by 87

  11. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

    Authors: Joyce F. Liu, William T. Barry, Michael J. Birrer, Jung Min Lee, Ronald J. Buckanovich, Gini F. Fleming, B.J. Rimel, Mary K. Buss, Sreenivasa Nattam, Jean Hurteau, Weixiu Luo, Philippa Quy, Christin Whalen, Lisa Obermayer, Hang Lee, Eric P. Winer, Elise C. Kohn, S. Percy Ivy, Ursula A. Matulonis - The Lancet Oncology 2014 cited by 584

  12. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

    Authors: Jung Min Lee, Ashley Cimino‐Mathews, Cody J. Peer, Alexandra S. Zimmer, Stanley Lipkowitz, Christina M. Annunziata, Liang Cao, Maria I. Harrell, Elizabeth M. Swisher, Nicole Houston, Dana‐Adriana Botesteanu, Janis M. Taube, Elizabeth Thompson, Aleksandra Ogurtsova, Haiying Xu, Jeffers Nguyen, Tony W. Ho, William D. Figg, Elise C. Kohn - Journal of Clinical Oncology 2017 cited by 240

  13. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

    Authors: J.F. Liu, William T. Barry, Michael J. Birrer, J.-M. Lee, Ronald J. Buckanovich, Gini F. Fleming, B.J. Rimel, Mary K. Buss, Sreenivasa Nattam, Jean Hurteau, Wenjie Luo, Jennifer Curtis, C. Whalen, Elise C. Kohn, S. Percy Ivy, Ursula A. Matulonis - Annals of Oncology 2019 cited by 189

  14. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

    Authors: Jennifer A. Chan, Susan M. Geyer, Tyler Zemla, Michael V. Knopp, Spencer C. Behr, Sydney Pulsipher, Fang‐Shu Ou, Amylou C. Dueck, Jared D. Acoba, Ardaman Shergill, Edward M. Wolin, Þorvarður R. Hálfdánarson, Bhavana Konda, Nikolaos A. Trikalinos, Bernard Tawfik, Nitya Raj, Shagufta Shaheen, Namrata Vijayvergia, Arvind Dasari, Jonathan Strosberg, Elise C. Kohn, Matthew H. Kulke, Eileen M. O’Reilly, Jeffrey A. Meyerhardt - New England Journal of Medicine 2024 cited by 136

  15. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

    Authors: Panagiotis A. Konstantinopoulos, Alexandre André Balieiro Anastácio da Costa, D. Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson, Bose Kochupurakkal, David L. Kolin, Elise C. Kohn, Joyce F. Liu, Elizabeth H. Stover, Jennifer Curtis, Nabihah Tayob, Madeline Polak, Dipanjan Chowdhury, Ursula A. Matulonis, Anniina Färkkilä, Alan D. D’Andrea, Geoffrey I. Shapiro - Nature Communications 2021 cited by 68

  16. Vaccination of Adults With Cancer: ASCO Guideline

    Authors: Mini Kamboj, Kari Bohlke, Deana M. Baptiste, Kieron Dunleavy, Abbey Fueger, Lee Jones, Amar H. Kelkar, Lisa Y. Law, Kristine B. LeFebvre, Per Ljungman, Eric D. Miller, Larissa A. Meyer, Heather Moore, Heloisa P. Soares, Randy Taplitz, Edom Seife Woldetsadik, Elise C. Kohn - Journal of Clinical Oncology 2024 cited by 108

  17. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

    Authors: Stéphanie Lheureux, Zhongwu Lai, Brian Dougherty, Sarah Runswick, Darren Hodgson, Kirsten M. Timms, Jerry S. Lanchbury, Stan Kaye, Charlie Gourley, David D.L. Bowtell, Elise C. Kohn, Clare L. Scott, Ursula A. Matulonis, Tony Panzarella, Katherine Karakasis, Julia V. Burnier, C. Blake Gilks, Mark J. O’Connor, Jane Robertson, Jonathan A. Ledermann, J. Carl Barrett, Tony W. Ho, Amit M. Oza - Clinical Cancer Research 2017 cited by 154

  18. The microenvironment of the tumour–host interface

    Authors: Lance A. Liotta, Elise C. Kohn - Nature 2001 cited by 2,333

  19. LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

    Authors: Jennifer A. Chan, Susan M. Geyer, F-S. Ou, Michael V. Knopp, Spencer C. Behr, Tyler Zemla, Jared D. Acoba, Ardaman Shergill, Edward M. Wolin, Þorvarður R. Hálfdánarson, Nikolaos A. Trikalinos, Bhavana Konda, N. Vijayvergia, N.A. Dasari, J. Strosberg, Elise C. Kohn, Matthew H. Kulke, Eileen M. O’Reilly, Jeffrey A. Meyerhardt - Annals of Oncology 2023 cited by 27

  20. New strategies in ovarian cancer treatment

    Authors: Jung‐Min Lee, Lori M. Minasian, Elise C. Kohn - Cancer 2019 cited by 121

  21. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

    Authors: J.-M. Lee, Jonathan A. Ledermann, Elise C. Kohn - Annals of Oncology 2013 cited by 356

  22. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment

    Authors: David A. Wheeler, Naoko Takebe, Toshinori Hinoue, Katherine A. Hoadley, Maria Cardenas, Alina M. Hamilton, Peter W. Laird, Linghua Wang, Adrienne Johnson, Ninad Dewal, Vincent A. Miller, David Piñeyro, Manuel Castro de Moura, Manel Esteller, Hui Shen, Jean C. Zenklusen, Roy Tarnuzzer, Lisa M. McShane, James V. Tricoli, P. Mickey Williams, Irina A. Lubensky, Geraldine O’Sullivan Coyne, Elise C. Kohn, Richard F. Little, Jeffrey D. White, Shakun Malik, Lyndsay N. Harris, Carol J. Weil, Alice P. Chen, Chris Karlovich, Brian Rodgers, Lalitha Shankar, Paula Jacobs, Tracy S. Nolan, Hai Hu, Donna M. Muzny, HarshaVardhan Doddapaneni, Viktoriya Korchina, Julie M. Gastier‐Foster, Jay Bowen, Kristen Leraas, Elijah F. Edmondson, James H. Doroshow, Barbara A. Conley, S. Percy Ivy, Louis M. Staudt - Cancer Cell 2020 cited by 104

  23. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

    Authors: Christina M. Annunziata, Elise C. Kohn, Patricia LoRusso, Nicole Houston, Robert L. Coleman, Manuela Buzoianu, Gabriel J. Robbie, Robert J. Lechleider - Investigational New Drugs 2012 cited by 117

  24. Neuroendocrine Tumors—Less Well Known, Often Misunderstood, and Rapidly Growing in Incidence

    Authors: Aman Chauhan, Elise C. Kohn, Jaydira Del Rivero - JAMA Oncology 2019 cited by 75